As outlined in a series of articles in the online open access publication, Malaria Journal, the World Antimalarial Resistance Network (WARN) aims to provide a globally co-ordinated effort to tackle the disease, which is estimated to kill between 1 and 2.7 million people every year.
One of the major aims of WARN is to facilitate worldwide monitoring and characterisation of drug resistance, particularly that to the latest generation of antimalarial drugs, artemisinin-based combination therapies (ACTs).
WARN will consist of four linked, global, open-access, web-based databases containing four kinds of data:·Clinical drug efficacy
WARN’s founders hope that the databases will help speed up the publication process for scientists. This, in turn, means that policymakers and malaria control managers will have access to timely information on the temporal and geographic trends of drug resistance, allowing them to take action as soon as resistant malaria parasites are detected.
Drug resistance is a major threat to the control and eradication of malaria and can lead to treatment failure, increased spread of the disease, and higher morbidity and mortality. Many ‘old’ antimalarials, including chloroquine and mefloquine, are now of limited use because of drug resistance.
Today, over 50 countries recommend ACTs as first-line therapy for falciparum malaria, the most severe form of the disease. While these newer treatments are currently effective, researchers know that resistance to ACTs will emerge in the future.
The network is being launched after a meeting of leading malaria researchers and policymakers sponsored by the Bill and Melinda Gates Foundation held at the Wellcome Trust/Sanger Centre, Cambridge, UK in late 2006.
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences